TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00849576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Human Insulin
Description: 0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: 90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin VIAject™ (75%)
Description: 75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin VIAject™ (90%)
Description: 90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
Study: NCT04211779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Real tDCS (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The active session of tDCS will consist in applying anodal stimulation over left M1 (C3 according to the 10-20 international EEG placement) and the cathodal stimulation over right supraorbital area (Fp2 according to the 10-20 international EEG placement), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham current (TCT Research Limited, Hong Kong); 3 times a week on alternate days for consecutive 6 weeks. The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: The Exercise intervention will include only aerobic exercise 3 times a week on alternate days for consecutive 6 weeks. The program will last 20 minutes.
Study: NCT01101620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levosimendan
Study: NCT02408367

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: 30 minutes endurance training at 75% of the Maximum heart rate

Intervention type: BEHAVIORAL
Intervention: Exercise
Description: 30 minutes endurance training at 75% of the Maximum heart rate

Intervention type: BEHAVIORAL
Intervention: Relaxation
Description: 30

Intervention type: BEHAVIORAL
Intervention: Relaxation
Description: 30
Study: NCT00669721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: law molecular weigth heparin
Description: administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractioned heparin
Description: administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
Study: NCT02312154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital
Description: stabilized hyaluronic acid (HA)-based gel of nonanimal origin
Study: NCT02070783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04919005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Environment
Description: The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Environment
Description: The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Environment
Description: The Virtual Environment was called SorrisoTur and consists of 10 mini-games with difficulty levels in a limited number of cities and mini-games distributed in a thematic scenario of the map of Brazil. The virtual environment consists of the cognitive training mini-games within a theme for all screens, mini-games, and information. The interventions with the Virtual Environment were administered in periods of one hour, twice a week, for a month.
Study: NCT01438203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrust manipulation
Description: Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-thrust manipulation
Description: Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
Study: NCT01571700

Intervention type: PROCEDURE
Intervention: Catheterization Pacing
Description: The second part of the study will include patients with pulmonary hypertension \>5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
Study: NCT00245570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: 1 dose montelukast 10 mg tablet given orally in one of three treatment periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: 1 dose montelukast 10 mg tablet given orally in one of three treatment periods
Study: NCT04031014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL EMSELLA Active treatment
Description: BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL EMSELLA Sham Treatment
Description: BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
Study: NCT03187379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
Study: NCT03187379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 60cc Bupivacaine
Study: NCT01347164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE life coaching intervention
Description: 6 2-hour sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Counseling
Description: Standard one-hour HIV counseling session
Study: NCT04322045

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multi-parametric MRI
Description: Multi-parametric MRI will be suggested for those PSA ≥4 ng/mL, PI-RADS v2 score will be used to evaluate images.
Study: NCT01676350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IO access using EZ-IO®
Description: IO line placed using an FDA-approved device called an EZ-IO®.
Study: NCT01991574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium acetate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Hydroxide Adipate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: methylcellulose capsules
Study: NCT00152854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 1g po qid
Study: NCT04138966

Intervention type: DEVICE
Intervention: Skin Conductance
Description: Measures skin conductance as a surrogate to nociception
Study: NCT04705740

Intervention type: OTHER
Intervention: ERCP
Description: ERCPs performed annually by an endoscopist

Intervention type: OTHER
Intervention: ERCP
Description: ERCPs performed annually by an endoscopist

Intervention type: OTHER
Intervention: ERCP
Description: ERCPs performed annually by an endoscopist
Study: NCT00152854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: acetaminophen 1g po qid for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo, sugar pill
Study: NCT02573467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study: NCT02133937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gantenerumab
Description: Single subcutaneous injection of a high concentration liquid formulation
Study: NCT02573467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Description: BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Study: NCT04361045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: StriveWeekly
Description: The intervention (app.striveweekly.com) delivered eight modules: introduction module, six skills modules, and wrap-up module. The two program brand name versions had identical content, but different aesthetic schemes. Modules were released week-by-week, and participants self-guided through content. To facilitate skills practice, every module was accompanied by: a weekly intro email and reminder emails; an extras section for tips/suggestions; and a weekly prize drawing. The Dashboard section of the intervention displayed user progress. The Campus section of this dashboard provided: campus-specific announcements; referrals to relevant campus wellness resources; and an anonymous livestream of all campus users' activity.~Strategies/skills included: Psychoeducation; Self-monitoring; Behavioral activation; Cognitive restructuring; Sleep hygiene; Time management; Interpersonal avoidance exposures; Physical exercise; Mindfulness; Maintenance planning.
Study: NCT04717180

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia rehabilitation using software program or conventional therapy
Description: Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aphasia rehabilitation using software program or conventional therapy
Description: Patients were randomized into two groups: group I who received therapy using the software aphasia rehabilitation program and group II who received conventional (traditional) language therapy
Study: NCT04250675

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent pneumatic leg compressions
Description: Patients will be asked to use the ArtAssist® device to compress the foot and ankle (120 mmHg) of both legs for 2 hours daily for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will be asked to use the ArtAssist® device to compress the foot and ankle (30 mmHg) of both legs for 2 hours daily for 3 months.
Study: NCT04040855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: Multi-professional medication review
Study: NCT00937911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study: NCT01495273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transtracheal injection
Description: Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
Study: NCT02133937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gantenerumab
Description: Single subcutaneous injection of a lyophilized formulation
Study: NCT01495273

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transtracheal injection
Description: Control group will undergo transtracheal injection with a standard needle/syringe assembly.
Study: NCT01144546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: passive leg raising (45 degree leg elevation for 1-2 min)
Description: the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
Study: NCT03515798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant EC-paclitaxel chemotherapy
Description: The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant EC-paclitaxel chemotherapy
Description: The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel
Study: NCT04296292

Intervention type: OTHER
Intervention: In-depth interviews
Description: In-depth interviews following a narrative line of enquiry and direct observation at each of the research sites
Study: NCT02611687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitolisant
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02993159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimoxifene
Description: Applied to the breast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Applied to the breast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Given PO
Study: NCT03545906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAM-UP Intervention Group
Description: Children randomly assigned to TEAM-UP will have a telemedicine assisted specialist visit scheduled after 4 weeks of initiating DOT at school, as well as 2 subsequent follow-up visits. The visits will be performed by a specialist in pediatric asthma, to implement guideline-based care. Prescriptions for asthma medications will be prescribed to be delivered as directly observed therapy in school.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care Comparison
Description: Similar to the TEAM-UP group, children in the Enhanced Care group will receive a symptom assessment and asthma education materials at baseline, and we will contact the PCP by facsimile or email and will recommend DOT of preventive asthma medication through school as well as a referral to specialist. However specialist visits will not be facilitated via telemedicine.
Study: NCT00811109

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Standard Hemodialysis
Description: Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: with Blood Volume Management (BVM®) only
Description: Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring
Description: Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
Study: NCT01033227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite injection, usp
Description: Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
Study: NCT01901588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intraoperative dose of intravenous placebo
Study: NCT01975480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Study: NCT02011464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel is infiltrated into posterior compartment for pain control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is infiltrated into posterior compartment for control
Study: NCT04834115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Tablets
Description: Oral ivermectin at a one time dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo at a one time dose
Study: NCT03612700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPFA-rich foods
Description: Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
Study: NCT01390935

Intervention type: OTHER
Intervention: guideline adherence
Description: guideline adherence of physician
Study: NCT04034680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME
Description: The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education-only intervention
Description: Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
Study: NCT01960842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel
Description: Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CADD-Legacy® 1400 ambulatory infusion pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG tube
Description: percutaneous endoscopic gastrostomy tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tube
Description: jejunal tube
Study: NCT00195052

Intervention type: DIAGNOSTIC_TEST
Intervention: Intrinsic signal imaging of human cortex
Description: Light is shined on the brain at 540 nm and 610 nm and images are acquired at 10 frames per second.
Study: NCT02021604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorodopa F 18
Description: A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
Study: NCT03161847

Intervention type: OTHER
Intervention: Non-interventional study
Description: Non-interventional study
Study: NCT02528136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT03648970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: The participant will be given pravastatin 2 x 20 mg per oral daily